Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.
Antibodies, Monoclonal, Humanized
Brain
/ diagnostic imaging
Double-Blind Method
Humans
Interferon beta-1a
/ analysis
Magnetic Resonance Imaging
/ methods
Multiple Sclerosis
/ pathology
Multiple Sclerosis, Relapsing-Remitting
/ diagnostic imaging
Myelin Sheath
/ pathology
Recurrence
Water
/ analysis
Demyelination
Interferon Beta-1a
Multiple Sclerosis
Myelin Water Imaging
Ocrelizumab
Remyelination
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
04
2022
revised:
27
06
2022
accepted:
10
07
2022
pubmed:
26
7
2022
medline:
25
8
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF). In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind period (DBP) followed by a two-year open label extension (OLE) with ocrelizumab treatment. MWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, 24, 48 and 96 (DBP), and weeks 144 and 192 (OLE), and in white matter for 23 healthy control participants at weeks 0, 48 and 96. Linear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for participants originally randomised to IFNb-1a compared to those originally randomised to OCR. Controls showed no change in MWF over 96 weeks in any region. Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tissue.
Sections du résumé
BACKGROUND
Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF).
OBJECTIVE
In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind period (DBP) followed by a two-year open label extension (OLE) with ocrelizumab treatment.
METHODS
MWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, 24, 48 and 96 (DBP), and weeks 144 and 192 (OLE), and in white matter for 23 healthy control participants at weeks 0, 48 and 96.
RESULTS
Linear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for participants originally randomised to IFNb-1a compared to those originally randomised to OCR. Controls showed no change in MWF over 96 weeks in any region.
CONCLUSION
Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tissue.
Identifiants
pubmed: 35878575
pii: S2213-1582(22)00174-7
doi: 10.1016/j.nicl.2022.103109
pmc: PMC9421448
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Water
059QF0KO0R
ocrelizumab
A10SJL62JY
Interferon beta-1a
XRO4566Q4R
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103109Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Mult Scler. 2018 Oct;24(12):1557-1568
pubmed: 28782447
J Magn Reson Imaging. 2011 Mar;33(3):713-8
pubmed: 21563257
Mult Scler. 2019 May;25(6):811-818
pubmed: 29663845
J Neuroimaging. 2021 Nov;31(6):1119-1125
pubmed: 34310789
IEEE Trans Med Imaging. 2001 Jan;20(1):45-57
pubmed: 11293691
Magn Reson Med. 2013 Jul;70(1):147-54
pubmed: 22915316
Hum Brain Mapp. 2019 May;40(7):2104-2116
pubmed: 30648315
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
J Magn Reson Imaging. 2007 Oct;26(4):1106-11
pubmed: 17896356
Neuroimage. 2012 Mar;60(1):263-70
pubmed: 22155325
Neurology. 2019 Mar 12;92(11):519-533
pubmed: 30787160
Brain Plast. 2016 Dec 21;2(1):71-91
pubmed: 29765849
Neuroimage. 2017 Feb 15;147:800-811
pubmed: 27729276
Sci Rep. 2021 Jan 11;11(1):269
pubmed: 33431990
J Neurol. 2004 Mar;251(3):284-93
pubmed: 15015007
Mult Scler. 2012 Aug;18(8):1125-34
pubmed: 22194217
Magn Reson Med. 2008 Dec;60(6):1372-87
pubmed: 19025904
Magn Reson Med. 1994 Jun;31(6):673-7
pubmed: 8057820
Neuroimage. 2021 Apr 15;230:117744
pubmed: 33524576
Neurology. 2016 Aug 30;87(9):905-11
pubmed: 27473139
Neurology. 2020 Sep 29;95(13):e1854-e1867
pubmed: 32690791
J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):851-8
pubmed: 24029546
Magn Reson Med. 2015 Nov;74(5):1227-35
pubmed: 26407635
PLoS One. 2015 Sep 18;10(9):e0137715
pubmed: 26381510
J Neuroimaging. 2020 Jul;30(4):537-543
pubmed: 32579281
Magn Reson Med. 2011 Apr;65(4):1021-35
pubmed: 21413066
IEEE Trans Biomed Eng. 2010 Nov;57(11):
pubmed: 20601307
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
J Neurol. 2017 Feb;264(2):304-315
pubmed: 27888416
Sci Rep. 2021 Jan 14;11(1):1369
pubmed: 33446710
Front Neurosci. 2018 Nov 21;12:854
pubmed: 30519158
J Magn Reson Imaging. 2013 Dec;38(6):1445-53
pubmed: 23553991
J Magn Reson Imaging. 2009 Aug;30(2):411-7
pubmed: 19629970
AJNR Am J Neuroradiol. 2020 Sep;41(9):1584-1591
pubmed: 32819894
Elife. 2020 Oct 21;9:
pubmed: 33084576
Magn Reson Med. 2015 Jan;73(1):161-9
pubmed: 24464472
Mult Scler. 2011 Aug;17(8):949-57
pubmed: 21502309
Neuroimage. 2008 Jan 1;39(1):336-47
pubmed: 17931890